Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about unit size escalation, not just volume. Let's review the transcript. Key points: Management discusses strong growth in CV, new business near record, but does it mention that deals are individually larger? They talk about "new business" but not about average deal size increasing. They mention "contract value" growth, but that could be from more clients or higher prices. They mention "retention" and "new business" but no explicit statement about the size of individual contracts increasing. They mention "conferences" and "consulting" but again, no mention of larger deals. They mention "backlog up 45%" but that could be from more projects, not necessarily larger ones. They mention "multi-year contracts" contributing to backlog growth, but that's about contract duration, not necessarily size per engagement. They say "contract optimization" business up, but no detail on size. The question specifically asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago?" There is no such statement. Management talks about strong demand, record new business, but not about the size of each deal increasing. They mention "near record new business" but that's total new business, not per deal. They mention "retention" but that's about keeping clients, not about expanding scope. They mention "conferences" with strong bookings, but not about larger conferences. They mention "consulting" with strong bookings, but not about larger projects. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.